Literature DB >> 22130725

[Combined retinal artery and vein occlusions associated with interferon beta therapy].

T Jenisch1, T Dietrich-Ntoukas, A B Renner, H Helbig, M A Gamulescu.   

Abstract

Interferon (IFN) beta is commonly used in the treatment of multiple sclerosis. Thromboembolic complications may be associated with this therapy. We describe a case of branch arterial occlusions combined with central vein occlusion in a female patient who had undergone IFN beta therapy for 10 years. Thromboembolic and cardiovascular risk factors responsible for this event were excluded. The appearance of retinal vein and artery occlusions in our patient indicates an association with the long-term use of IFN beta.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22130725     DOI: 10.1007/s00347-011-2448-0

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  10 in total

1.  Interferon-associated combined branch retinal artery and central retinal vein obstruction.

Authors:  Juan E Rubio; Steve Charles
Journal:  Retina       Date:  2003-08       Impact factor: 4.256

2.  Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C.

Authors:  S Sugano; T Suzuki; M Watanabe; K Ohe; K Ishii; T Okajima
Journal:  Am J Gastroenterol       Date:  1998-12       Impact factor: 10.864

Review 3.  Interferon associated retinopathy.

Authors:  S Hayasaka; Y Nagaki; M Matsumoto; S Sato
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

4.  Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.

Authors:  K Jain; W C Lam; S Waheeb; Q Thai; J Heathcote
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

5.  Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

Authors:  L Kappos; A Traboulsee; C Constantinescu; J-P Erälinna; F Forrestal; P Jongen; J Pollard; M Sandberg-Wollheim; C Sindic; B Stubinski; B Uitdehaag; D Li
Journal:  Neurology       Date:  2006-09-26       Impact factor: 9.910

6.  The human interferon alpha/beta receptor: characterization and molecular cloning.

Authors:  D Novick; B Cohen; M Rubinstein
Journal:  Cell       Date:  1994-05-06       Impact factor: 41.582

7.  Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a.

Authors:  Peter Joseph Jongen; Christian Sindic; Herwig Carton; Cees Zwanikken; Wim Lemmens; George Borm
Journal:  J Neurol       Date:  2009-11-18       Impact factor: 4.849

8.  Retinopathy: an overlooked adverse effect of interferon-beta treatment of multiple sclerosis.

Authors:  Masayuki Ohira; Daisuke Ito; Toshihiko Shimizu; Mamoru Shibata; Hisao Ohde; Norihiro Suzuki
Journal:  Keio J Med       Date:  2009-03

9.  Human leukocyte and fibroblast interferons are structurally related.

Authors:  T Taniguchi; N Mantei; M Schwarzstein; S Nagata; M Muramatsu; C Weissmann
Journal:  Nature       Date:  1980-06-19       Impact factor: 49.962

10.  Interferon-associated retinopathy.

Authors:  D R Guyer; J Tiedeman; L A Yannuzzi; J S Slakter; D Parke; J Kelley; R A Tang; M Marmor; G Abrams; J W Miller
Journal:  Arch Ophthalmol       Date:  1993-03
  10 in total
  4 in total

Review 1.  Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature.

Authors:  Lorenzo Gaetani; Paola S Menduno; Francesco Cometa; Maria Di Gregorio; Paola Sarchielli; Carlo Cagini; Paolo Calabresi; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2015-08-21       Impact factor: 4.849

Review 2.  Ocular side effects of biological agents in oncology: what should the clinician be aware of?

Authors:  Tobias Hager; B Seitz
Journal:  Onco Targets Ther       Date:  2013-12-24       Impact factor: 4.147

Review 3.  Ocular adverse events from pharmacological treatment in patients with multiple sclerosis-A systematic review of the literature.

Authors:  Juliana Muñoz-Ortiz; Juliana Reyes-Guanes; Estefanía Zapata-Bravo; Laura Mora-Muñoz; Juan Antonio Reyes-Hurtado; Luis Octavio Tierradentro-García; William Rojas-Carabali; Marcela Gómez-Suarez; Alejandra de-la-Torre
Journal:  Syst Rev       Date:  2021-10-28

4.  Comorbidities in combined retinal artery and vein occlusions.

Authors:  Dieter Schmidt
Journal:  Eur J Med Res       Date:  2013-08-16       Impact factor: 2.175

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.